Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > DRD1


Brief Information

Name:Dopamine D1 receptor
Target Synonym:D(1A) dopamine receptor,DRD1,Dopamine Receptor D1,Dopamine D1 Receptor,DRD1A,DADR,Receptors, Dopamine D1
Number of Launched Drugs:10
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
DR1-H52P6 Human Human DRD1 Full Length Protein (VLP)
ACRO Quality

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Docarpamine TA-870; TA-8704 Approved Tanadopa Heart Failure null 1994-01-01 Heart Failure Details
Olanzapine/Fluoxetine hydrochloride OFC Approved Eli Lilly And Company Symbyax United States Bipolar Disorder Eli Lilly And Company 2003-12-24 Depressive Disorder, Major; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Treatment-Resistant Details
Zuclopenthixol Hydrochloride LU-0108 Approved Clopixol Bipolar Disorder; Schizophrenia null 1962-01-01 Schizophrenia; Bipolar Disorder Details
Methylergometrine Maleate Approved Metenarin, Methergine, Ryegonivin, Basofortina, Methylergobrevin Postpartum Hemorrhage; Uterine Cervical Incompetence; Uterine Hemorrhage; Uterine Inertia Details
Samidorphan/Olanzapine ALKS-3831 Approved Alkermes Plc Lybalvi United States Bipolar Disorder; Schizophrenia Alkermes Inc 2021-05-28 Schizophrenia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Alcoholism Details
Olanzapine LY-170053; INP-105; TEV-‘749; LY-170052; ALKS-7921 Approved Eli Lilly And Company Zyprexa Relprevv, Olansek, Zyprexa Zydis, Olanzapine ODF, 再普乐, Midax, Lanzac, Zyprexa, Zypadhera, Zalasta, Zyprexa Velotab EU Schizophrenia; Bipolar Disorder null 1996-09-27 Opioid-Related Disorders; Chemotherapy-induced nausea and vomiting; Fasting; Anorexia Nervosa; Borderline Personality Disorder; Depressive Disorder, Treatment-Resistant; Gambling; Nausea; Vomiting; Postoperative Nausea and Vomiting; Emergence Delirium; Feeding and Eating Disorders; Malaria, Falciparum; Autistic Disorder; Hematologic Neoplasms; Neoplasms; Insulin Resistance; Anorexia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Depression; Stomach Neoplasms; Depressive Disorder, Major; Schizophrenia; Substance-Related Disorders; Weight Loss; Solid tumours Details
Phenylpropanolamine Hydrochloride Approved Nasadec, Nasathera, Pararhinol Nasal Obstruction Details
Fenoldopam Mesylate SKF-82526; SKF-82526J; (±)-SKF-82526 Approved Abbott Laboratories Corlopam United States Hypertension Hospira Inc 1997-09-23 Hypertension Details
Olanzapine/Hydroxyzine pamoate Approved Nausea Details
Stepholidine Approved Mainland China Headache; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome; Migraine Disorders null 1995-01-01 Headache; Migraine Disorders; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ecopipam PSYRX-101; Sch-39166 Phase 3 Clinical Merck Sharp & Dohme Corp Language Disorders; Speech Disorders; Self-Injurious Behavior; Lesch-Nyhan Syndrome; Childhood-Onset Fluency Disorder; Tourette Syndrome; Gambling; Stuttering Details
Tavapadon CVL-751; PF-6649751; PF-06649751 Phase 3 Clinical Pfizer Inc, Cerevel Therapeutics Llc Kidney Diseases; Parkinson Disease; Hepatic Insufficiency Details
Thioridazine TP-21 Phase 3 Clinical Novartis Pharma Ag Schizophrenia; Anxiety Disorders; Carcinoma, Hepatocellular Details
Olanzapine long acting injectable (Teva Pharmaceutical Industries) TV-44749; TEV-‘749; mdc-TJK Phase 3 Clinical Medincell SA Schizophrenia Details
PF-06412562 PF-6412562; PF-06412562 Phase 2 Clinical Pfizer Inc Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders; Parkinson Disease Details
Mevidalen LY-3154207 Phase 2 Clinical Eli Lilly And Company Parkinson Disease; Lewy Body Disease Details
TGOF02N TGOF-02N; TGOF02N; FKF02SC Phase 2 Clinical Fabre-Kramer Schizophrenia Details
ASP-4345 ASP-4345 Phase 2 Clinical Astellas Pharma Inc Schizophrenia Details
Docarpamine (Martin Pharmaceuticals) Phase 2 Clinical Martin Pharmaceuticals Inc Gastrointestinal Diseases; Liver Cirrhosis; Mouth Diseases Details
CVL-871 CVL-871 Phase 2 Clinical Pfizer Inc Dementia Details
[11C]NNC-112 [11C]NNC-112 Phase 2 Clinical Glaxosmithkline Plc Diagnostic agents Details
Lu-AF-28996 Phase 1 Clinical H. Lundbeck A/S Parkinson Disease Details
Olanzapine intranasal (Neurelis) NRL-4; NRL-1004 Phase 1 Clinical Neurelis Inc Bipolar Disorder Details
Oxytocin/Methylergometrine Maleate Phase 1 Clinical Nanjing Gritpharma Co Ltd Hemorrhage; Obstetric Labor Complications Details
ITI-333 ITI-333 Phase 1 Clinical Intra-Cellular Therapies Inc Mood Disorders; Pain; Opioid-Related Disorders Details
PF-06730110 PF-06730110; [18F]MNI-968 Phase 1 Clinical Invicro Llc Nerve Degeneration Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message